Home Previous Slide◀︎ Next Slide▶︎ We act with care to create value in the lives of the people we serve We always strive to find new ways to deliver solutions to people living with severe diseases Everyone deserves to live the best life that they can Current Slide Current Slide Current Slide
At UCB, we believe that everyone deserves to live the best life that they can. That’s why - as a global biopharmaceutical leader - we’re focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. Discover more about us UCBCares® UCBCares® is a personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine Contact us here A home for innovation Innovation is a key driver of progress in every aspect of human life including advancing healthcare. Find out more Learn more Empowering women of childbearing age UCB net-zero targets validated by the Science Based Targets initiative Discover the Unbearable Home UCB Stories & Newsroom Story 11 Jun 2025 Shining a light on myasthenia gravis: UCB marks MG Awareness Month and previews ‘Faces of MG’ Read More Story 11 Jun 2025 Are traditional clinical trials on the brink of obsolescence? Read More Press release 11 Jun 2025 BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of... Read More Press release 19 May 2025 UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences Read More “Every breakthrough we achieve brings us closer to a world where patients can live better, healthier lives.” Sustainability Sustainability is at the heart of everything we do at UCB, guiding our decisions to positively impact society, support communities, and protect the planet for future generations. Learn more UCB ventures UCB Ventures invests in pioneering companies and technologies that have the potential to transform the lives of people living with severe diseases. Learn more ×
Story 11 Jun 2025 Shining a light on myasthenia gravis: UCB marks MG Awareness Month and previews ‘Faces of MG’ Read More
Press release 11 Jun 2025 BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of... Read More
Press release 19 May 2025 UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences Read More